Makes FDA-cleared breath-testing devices that measure airway inflammation to help doctors manage asthma.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- FinancialsHigh structural barrier to entry
Makes FDA-cleared breath-testing devices that measure airway inflammation to help doctors manage asthma.
What this company is and how it runs — written from structure, not news.
NIOX Group makes devices that measure nitric oxide in a patient's exhaled breath, which doctors use as a direct indicator of airway inflammation to guide asthma treatment. The device works because built-in audio and visual cues coach the patient to exhale at exactly the flow rate the onboard algorithm assumes — vary that rate and the reading shifts regardless of what is actually happening in the lungs, so the guidance system is what makes the measurement repeatable across different nurses, hospitals, and countries. Because the FDA 510(k) and CE clearances were granted to that specific combination of sensor, algorithm, and breath-sampling interface together, a competitor cannot simply build a better sensor and inherit those approvals; they have to run new clinical validation studies and restart the entire regulatory cycle from scratch. The single point of fragility is the breath-sampling mechanism itself — if it were knocked out by a patent challenge or a manufacturing failure, the cleared device configuration would cease to exist, and the clinical data needed to approve any replacement design does not yet exist either.
How does this company make money?
The company earns money each time it sells a NIOX VERO or FeNO by NIOX device to a healthcare facility. It then continues to earn from that same facility over time, because the devices require consumable sensor replacements and calibration services to keep working — so ongoing use of the device generates repeat purchases after the initial sale.
What makes this company hard to replace?
Hospitals that have connected NIOX devices to their electronic health record systems have already done the technical work to make that data flow, and switching to a different device means doing that integration work again. Clinicians and staff have also been trained on how to run the test and interpret FeNO results from these specific devices, and that training represents real time already spent. On top of that, any alternative FeNO device would need to complete its own lengthy regulatory validation studies before a hospital could legally substitute it, so the switch is not simply a purchasing decision.
What limits this company?
Each electrochemical nitric oxide sensor has to be manufactured from specialised materials and then calibrated against the exact same algorithm used in the cleared device. That calibration process, not factory speed or chip supply, sets the ceiling on how many cleared, usable devices can be made and shipped in a given period.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance and CE marking, because without those approvals no hospital can legally use the device. It also relies on electrochemical nitric oxide sensors, microprocessor components from electronic suppliers, and ISO 13485 certified manufacturing facilities. Its ability to reach customers depends on its own direct sales operations in the UK, US, Germany, Sweden, and China.
Who depends on this company?
Pulmonologists and primary care physicians use NIOX devices to measure airway inflammation and decide how to adjust a patient's asthma treatment. Hospital respiratory departments that run patient monitoring programs would lose the only objective, quantitative inflammation reading they currently have. Asthma management programs across healthcare systems would have to fall back on tracking symptoms alone, with no biomarker data to guide decisions.
How does this company scale?
Once the algorithms and manufacturing processes have been validated, producing additional device units adds relatively little extra cost on the software and design side. What does not get cheaper or faster as the company grows is entering new countries — each new geography requires its own clinical studies, its own regulatory filings, and its own approval cycle, and none of that can be automated or handed off to a third party to speed up.
What external forces can significantly affect this company?
Whether healthcare systems and insurers agree to reimburse FeNO testing directly affects how often doctors order the test and therefore how much the devices are used. Because the company sells in the UK, US, Europe, and Asia, swings in currency exchange rates hit its profit margins across those markets. Post-Brexit trade rules also create friction between the company's UK headquarters and its EU operations, affecting how devices and approvals move across that border.
Where is this company structurally vulnerable?
If the proprietary breath-sampling mechanism were blocked by a successful intellectual property challenge, or if a component failure made it impossible to manufacture, the specific device configuration named in the FDA 510(k) and CE approvals could no longer be produced. Those approvals attach to that exact combination of sensor, algorithm, and breath interface, so losing the ability to make that combination would mean losing the legal right to sell in the company's main markets — and no replacement design would yet have the clinical data needed to get back through the approval process.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Three observations co-occur: dividend payments are large relative to net income (high payout ratio), free cash flow has been positive each of the last three years, and the industry-benchmarked equity ratio is elevated. The high payout ratio happens alongside multi-year FCF positivity and equity-heavy capital structure.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
Three observations have aligned: retained earnings are a substantial share of total assets, the equity-to-assets ratio is elevated, and current-period dividend payments are a high share of net income (the dividend-payout-intensity observation scores in the upper portion of its 0–100% mapped range).
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
How is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph